The Investigation of New Biological Markers for Prostate Cancer Diagnosis and Management in Chinese Population

Launched by CHINESE UNIVERSITY OF HONG KONG · Mar 26, 2019

Keywords

ClinConnect Summary

This clinical trial is looking into new biological markers that could help diagnose and manage prostate cancer more effectively in Chinese men. Prostate cancer is a significant health issue, especially in Hong Kong, where over 1,600 new cases are diagnosed each year. Currently, the most common test used, called PSA (Prostate-Specific Antigen), is not always reliable. It can show high levels for reasons other than cancer, and it doesn’t always indicate how serious the cancer might be. This trial aims to find better ways to identify prostate cancer by studying new markers that could improve patient care and outcomes.

To be eligible for this study, participants need to be adult Chinese males aged 18 and older who have been identified as possibly having prostate cancer, either through a physical exam or an abnormal PSA test result. Those who are interested in participating will undergo tests to evaluate these new markers. It’s important to note that anyone who refuses or cannot give consent will not be able to take part in the trial. This research could lead to better diagnostic tools and treatments for prostate cancer, ultimately helping patients receive more personalized care.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • 1. Adult Chinese male patients with age \> 18 years old
• • 2. Clinical suspected to have prostate cancer, based on abnormal digital rectal examination or elevated serum PSA level
• Exclusion Criteria:
• • 1. Patient refused or unable to provide consent for the study